Do global clinical trials make the $100-200mn Indian NCE a mirage?
This article was originally published in Scrip
Indian industry pundits now have very mixed views on whether the $100-200 million once touted as the potential cost to develop and market an Indian new chemical entity (NCE) - just 10-20% of the globally accepted $1 billion figure - is truly feasible. Co-development and licensing options for NCEs are now high on the agenda of most Indian R&D firms as they evolve, more so in the absence of risk capital.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.